Vytorin's label gets makeover to include SHARP results - Cardiovascular Business PDF Print

Vytorin's label gets makeover to include SHARP results
Cardiovascular Business
In the SHARP (Study of Heart And Renal Protection) trial, Vytorin 10/20 mg lowered LDL-cholesterol in patients with moderate to severe chronic kidney disease (CKD), and major vascular events were reduced in the treatment group compared to placebo.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.